| Inflammatory Bowel Disease | Lifetime | 16 | CA 4 | 99.87 |
| Microscopic Colitis | Lifetime | 14 | CA 3 | 99.85 |
| Autoimmune and Inflammatory Disorders | Lifetime | 11 | CA 2 | 99.82 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 66 | CA 3 | 99.56 |
| Eosinophilic Esophagitis | Lifetime | 70 | CA 7 | 99.51 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 121 | CA 11 | 99.05 |
| Biosimilars and Bioanalytical Methods | Lifetime | 149 | CA 12 | 97.00 |
| Diagnosis and treatment of tuberculosis | Lifetime | 277 | CA 12 | 96.47 |
| Celiac Disease Research and Management | Lifetime | 319 | CA 13 | 95.84 |
| Diverticular Disease and Complications | Lifetime | 494 | CA 18 | 96.05 |
| Liver Diseases and Immunity | Lifetime | 500 | CA 25 | 96.23 |
| Pregnancy and Medication Impact | Lifetime | 717 | CA 64 | 93.54 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 865 | CA 37 | 67.54 |
| Inflammatory Bowel Disease | 2021-2025 | 9 | CA 1 | 99.90 |
| Microscopic Colitis | 2021-2025 | 7 | CA 1 | 99.89 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 15 | CA 1 | 99.46 |
| Eosinophilic Esophagitis | 2021-2025 | 22 | CA 1 | 99.29 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 7 | CA 1 | 99.48 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 47 | CA 2 | 98.48 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 51 | CA 3 | 96.40 |
| Helicobacter pylori-related gastroenterology studies | 2021-2025 | 118 | CA 4 | 96.20 |
| Celiac Disease Research and Management | 2021-2025 | 43 | CA 3 | 95.16 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 557 | CA 15 | 94.48 |
| Liver Diseases and Immunity | 2021-2025 | 162 | CA 9 | 94.12 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 92 | CA 6 | 91.08 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 530 | CA 6 | 93.80 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 243 | CA 7 | 88.34 |
| Tuberculosis Research and Epidemiology | 2021-2025 | 773 | CA 17 | 90.64 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 446 | CA 1 | 86.13 |
| Pregnancy and Medication Impact | 2021-2025 | 563 | CA 31 | 80.36 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 535 | CA 7 | 74.73 |
| Gastrointestinal motility and disorders | 2021-2025 | 944 | CA 25 | 75.87 |
| Diverticular Disease and Complications | 2021-2025 | 849 | CA 38 | 72.24 |
| Gastrointestinal Bleeding Diagnosis and Treatment | 2021-2025 | 929 | CA 30 | 62.59 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 991 | CA 40 | 42.98 |
